25/08/2021 iAH Interface de pesquisa - Lista

BIREME/OPAS/OMS - Biblioteca Virtual em Saúde

Base de dados : MEDLINE

Pesquisa : Radiotherapy [Palavras do título] and Cardiotoxicity

[Palavras do título]
Total de referências : 10

1/10
[PMID]: 25827153
[Au] Autor: Aleman BM; van Leeuwen FE
[Ad] Endereço: Antoni van Leeuwenhoek/Nederlands Kanker Instituut, Amsterdam.
[Ti] Título: [Hypofractionated adjuvant radiotherapy for breast cancer: no signs of increased risk
of cardiotoxicity].
[Ti] Título: Hypofractionering van bestraling voor borstkanker: geen aanwijzingen voor verhoogd
risico op hartschade?.
[So] Source: Ned Tijdschr Geneeskd;159:A8856, 2015.
[Is] ISSN: 1876-8784
[Cp] País de
publicação: Netherlands
[La] Idioma: dut
[Ab] Resumo: Adjuvant radiotherapy is frequently used in women with breast cancer to improve
both local control of the tumour and overall survival. Hypofractionated regimens are
increasingly being used as they involve fewer treatment sessions and, in terms of
tumour control, the effects of conventionally fractionated and hypofractionated
radiotherapy seem to be comparable. However, there is concern regarding increased
cardiotoxicity following hypofractionated radiotherapy treatment to the left side. In
order to determine if cardiac mortality increases with hypofractionation relative to
conventional fractionation, a Canadian research group performed a retrospective
analysis in 5334 women with breast cancer treated between 1990-1998 with
postoperative radiotherapy to the breast/chest wall only. At 15-year follow-up the
authors concluded that cardiac mortality was not statistically different among
patients with left-sided breast cancer whether treated with hypofractionated or
conventionally fractionated whole breast/chest wall irradiation. This commentary
discusses the data presented in the paper, puts them into perspective and describes
the clinical implications.
[Mh] Termos MeSH Neoplasias da Mama/radioterapia
primário:
Cardiopatias/etiologia
Coração/efeitos da radiação
Lesões por Radiação/etiologia
[Mh] Termos MeSH Feminino
secundário:
Seres Humanos
[Pt] Tipo de
publicação: COMMENT;
ENGLISH ABSTRACT; JOURNAL ARTICLE
[Em] Mês de
entrada: 1505
[Cu] Atualização por
classe: 150401
[Lr] Data última
revisão: 150401
[Sb] Subgrupo de
revista: IM
[Da] Data de entrada
para 150402
processamento:
[St] Status: MEDLINE

2/10
[PMID]: 25017999
[Au] Autor: Basu S; Borde C; Kand P
[Ad] Endereço: Radiation Medicine Centre, Bhabha Atomic Research Centre, Tata Memorial Hospital
Annexe Building, Jerbai Wadia Road, Parel, Mumbai 400 012, Maharashtra, India.
Electronic address: drsanb@yahoo.com.
[Ti] Título: Increasing cardiac ¹8F-fluorodeoxyglucose (FDG) uptake on PET-CT as a biomarker

bases.bireme.br/cgi-bin/wxislind.exe/iah/online/ 1/8
25/08/2021 iAH Interface de pesquisa - Lista

for cardiotoxicity of chemo-radiotherapy in cancer: a myth or a reality?

[So] Source: Radiother Oncol;112(3):451-2, 2014 Sep.
[Is] ISSN: 1879-0887
[Cp] País de
publicação: Ireland
[La] Idioma: eng
[Mh] Termos MeSH Fluordesoxiglucose F18
primário:
Coração/diagnóstico por imagem
Neoplasias Pulmonares/cirurgia
Tomografia por Emissão de Pósitrons/métodos
Compostos Radiofarmacêuticos
Radiocirurgia
[Mh] Termos MeSH Feminino
secundário:
Seres Humanos
Masculino
[Pt] Tipo de
publicação:
LETTER; COMMENT
[Nm] Nome de
substância: 0 (Radiopharmaceuticals); 0Z5B2CJX4D (Fluorodeoxyglucose F18)
[Em] Mês de
entrada:
1505
[Cu] Atualização por
classe:
161125
[Lr] Data última
revisão:
161125
[Sb] Subgrupo de
revista:
IM
[Da] Data de entrada
para 140715
processamento:
[St] Status: MEDLINE

3/10
[PMID]: 24991199
[Au] Autor: Marinko T; Dolenc J; Bilban-Jakopin C
[Ad] Endereço: Department of Radiotherapy, Institute of Oncology Ljubljana, Ljubljana, Slovenia.
[Ti] Título: Cardiotoxicity of concomitant radiotherapy and trastuzumab for early breast cancer.
[So] Source: Radiol Oncol;48(2):105-12, 2014 Jun.
[Is] ISSN: 1318-2099
[Cp] País de
publicação:
Slovenia
[La] Idioma: eng
[Ab] Resumo: BACKGROUND: Trastuzumab therapy given in combination with one of several
chemotherapy regimens is currently considered the standard of care for the
treatment of early-stage, human epidermal growth factor receptor-2 (HER2) -positive
breast cancer. The treatment with trastuzumab is due to a significant impact on the
survival part of the standard adjuvant treatment of patients with HER2-positive breast
cancer. Patients treated with postoperative breast or chest wall irradiation receive
trastuzumab concomitant with radiotherapy. In a small proportion of patients
trastuzumab causes cardiotoxicity. Preclinical findings indicate a radiosensibilizing
effect of trastuzumab in breast cancer cells, but it is not yet clear whether it
radiosensibilizes cells of healthy tissues too. CONCLUSIONS: Special attention is
required when left breast or left thoracic wall is irradiated in patient receiving
trastuzumab, because long-term effects of the concurrent treatment with
trastuzumab and radiotherapy are not yet known. In an era where more patients are
surviving a diagnosis of breast cancer, better understanding and earlier detection of
therapy-induced cardiac toxicity will be of paramount importance.
[Pt] Tipo de
publicação: JOURNAL
ARTICLE; REVIEW
[Em] Mês de
entrada: 1407
[Cu] Atualização por
classe: 170220
[Lr] Data última
revisão: 170220
[Da] Data de entrada
para 140704
processamento:
bases.bireme.br/cgi-bin/wxislind.exe/iah/online/ 2/8
25/08/2021 iAH Interface de pesquisa - Lista
[St] Status: PubMed-not-MEDLINE
[do] DOI: 10.2478/raon-2013-0040

4/10
[PMID]: 24880968
[Au] Autor: Nagykálnai T; Nagy AC; Landherr L
[Ad] Endereço: XV. kerületi Szakrendelo Onkológia Budapest.
[Ti] Título: [Postoperative radiotherapy of breast cancer and cardiotoxicity].
[Ti] Título: Posztoperatív emlobesugárzás és cardiotoxicitas..
[So] Source: Orv Hetil;155(23):897-902, 2014 Jun 08.
[Is] ISSN: 0030-6002
[Cp] País de
publicação:
Hungary
[La] Idioma: hun
[Ab] Resumo: Cardiac complications may present a particular problem following radiation treatment
applied to the mediastinum and thoracic wall (and especially to the left breast).
Exposure of the heart during radiotherapy increases the risk of ischemic heart
disease occurring generally years after the treatment. The incidence of radiation
cardiotoxicity depends on various factors related to oncological therapies and the
patient (details of radiotherapy, age, gender, comorbidities, smoking habits, etc.).
Until recently the majority of clinical studies reported increased cardiac morbidity in
patients receiving radiation treatment of the chest wall and the breast. Due to modern
methods, however, postoperative chest wall and left breast irradiation is much safer
today than previously. In order to avoid cardiotoxicity, adherence to clinical practice
guidelines for chemo- and targeted therapy of breast cancer, use of the most
advanced irradiation procedures, regular monitoring of patients, and close
cooperation between cardiologists and oncologists are all recommended.
[Mh] Termos MeSH Neoplasias da Mama/radioterapia
primário:
Neoplasias da Mama/cirurgia
Coração/efeitos da radiação
Isquemia Miocárdica/etiologia
Lesões por Radiação/complicações
Radioterapia Adjuvante/efeitos adversos
[Mh] Termos MeSH Cardiologia
secundário:
Feminino
Seres Humanos
Comunicação Interdisciplinar
Mastectomia Segmentar
Oncologia
Período Pós-Operatório
Lesões por Radiação/etiologia
[Pt] Tipo de
publicação: ENGLISH
ABSTRACT; JOURNAL ARTICLE; REVIEW
[Em] Mês de
entrada: 1408
[Cu] Atualização por
classe: 140602
[Lr] Data última
revisão: 140602
[Sb] Subgrupo de
revista: IM
[Da] Data de entrada
para 140602
processamento:
[St] Status: MEDLINE
[do] DOI: 10.1556/OH.2014.29890

5/10
[PMID]: 22087448
[Au] Autor: Tzonevska A; Tzvetkov K; Atanasova M; Chakarova A; Piperkova E
[Ad] Endereço: Department of Nuclear Medicine, SHAT Oncology,1756 Sofia, Bulgaria.
dr.tzonevska@gmail.com.
[Ti] Título: Myocardial scintigraphy, echocardiography and proBNP for early detection of

bases.bireme.br/cgi-bin/wxislind.exe/iah/online/ 3/8
25/08/2021 iAH Interface de pesquisa - Lista

myocardial cardiotoxicity in breast cancer patients after chemo-radiotherapy.

[So] Source: Hell J Nucl Med;14(3):269-73, 2011 Sep-Dec.
[Is] ISSN: 1790-5427
[Cp] País de
publicação:
Greece
[La] Idioma: eng
[Ab] Resumo: The most severe side effect in breast cancer patients, treated with chemotherapy
and/or radiotherapy is cardiotoxicity, leading to chronic heart failure and worsening
the quality of life. The aim of our study was to detect early in these patients signs of
cardiotoxicity. Twenty four breast cancer patients were included in our study after
combined treatment (chemo and radiotherapy). We studied myocardial function by
gated single photon emission tomography (GSPET-MS), echocardiography (EC) and
32 amino acid polypeptide B-type natriuretic peptide (ProBNP) measurements. We
found early signs of cardiotoxicity in 10/24 investigated patients. All patients had no
clinical symptoms, and normal electrocardiogram and left ventricular ejection fraction
(LVEF). According to results from the performed tests, patients were divided in 4
groups: a) Normal systolic and diastolic LV function, normal ProBNP value, normal
myocardial scintigraphy in 14/24 patients. b) Diastolic dysfunction, increased
ProBNP value, hypoperfused defects in myocardial scintigraphy in 5/24 patients. c)
Diastolic dysfunction, normal ProBNP value, hypoperfused defects in myocardial
scintigraphy in 3/24 patients. d) Normal systolic and diastolic LV function, normal
ProBNP value, hypoperfused defects in myocardial scintigraphy in 2/24 patients. In
conclusion, in patients with breast cancer and asymptomatic cardiotoxicity, by
applying GSPET-MS, ProBNP measurements and EC diastolic function tests, we
detected early signs of myocardial damage in 10/24 patients 6-12 months after
chemotherapy and radiotherapy.
[Mh] Termos MeSH Cardiotoxicidade
primário:
Imagem de Perfusão do Miocárdio
[Mh] Termos MeSH Biomarcadores
secundário:
Neoplasias da Mama
Detecção Precoce de Câncer
Ecocardiografia
Seres Humanos
Peptídeo Natriurético Encefálico
Qualidade de Vida
Disfunção Ventricular Esquerda
[Pt] Tipo de
publicação:
JOURNAL ARTICLE
[Nm] Nome de
substância:
0 (Biomarkers); 114471-18-0 (Natriuretic Peptide, Brain)
[Em] Mês de
entrada: 1604
[Cu] Atualização por
classe: 111117
[Lr] Data última
revisão: 111117
[Sb] Subgrupo de
revista: IM
[Da] Data de entrada
para 111117
processamento:
[St] Status: MEDLINE

6/10
[PMID]: 20555097
[Au] Autor: Bovelli D; Plataniotis G; Roila F; ESMO Guidelines Working Group
[Ad] Endereço: Department of Cardiology, Santa Maria Hospital, Terni, Italy.
[Ti] Título: Cardiotoxicity of chemotherapeutic agents and radiotherapy-related heart disease:
ESMO Clinical Practice Guidelines.
[So] Source: Ann Oncol;21 Suppl 5:v277-82, 2010 May.
[Is] ISSN: 1569-8041
[Cp] País de
publicação: England
[La] Idioma: eng
[Mh] Termos MeSH Antineoplásicos/efeitos adversos
primário:

bases.bireme.br/cgi-bin/wxislind.exe/iah/online/ 4/8
25/08/2021 iAH Interface de pesquisa - Lista

Cardiopatias/tratamento farmacológico
Radioterapia/efeitos adversos
[Mh] Termos MeSH Antineoplásicos/uso terapêutico
secundário:
Neoplasias da Mama/radioterapia
Europa (Continente)/epidemiologia
Feminino
Cardiopatias/etiologia
Doença de Hodgkin/radioterapia
Seres Humanos
Incidência
Metanálise como Assunto
Fatores de Risco
[Pt] Tipo de
publicação:
JOURNAL ARTICLE; PRACTICE GUIDELINE
[Nm] Nome de
substância:
0 (Antineoplastic Agents)
[Em] Mês de
entrada:
1012
[Cu] Atualização por
classe:
161017
[Lr] Data última
revisão:
161017
[Sb] Subgrupo de
revista:
IM
[Da] Data de entrada
para 100618
processamento:
[St] Status: MEDLINE
[do] DOI: 10.1093/annonc/mdq200

7/10
[PMID]: 18976826
[Au] Autor: Shaffer R; Tyldesley S; Rolles M; Chia S; Mohamed I
[Ad] Endereço: British Columbia Cancer Agency, Vancouver, Canada.
[Ti] Título: Acute cardiotoxicity with concurrent trastuzumab and radiotherapy including internal
mammary chain nodes: a retrospective single-institution study.
[So] Source: Radiother Oncol;90(1):122-6, 2009 Jan.
[Is] ISSN: 0167-8140
[Cp] País de
publicação:
Ireland
[La] Idioma: eng
[Ab] Resumo: PURPOSE: To examine the acute cardiotoxicity of internal mammary chain (IMC)
irradiation with concurrent trastuzumab. MATERIALS AND METHODS: Clinical and
cardiac function data were collected on 59 patients with early breast cancer who
were treated with adjuvant trastuzumab and chemotherapy with or without
radiotherapy (often including IMC) at BC Cancer Agency in 2005. RESULTS: Forty-
four of fifty-nine patients received adjuvant radiotherapy (RT). Thirteen had left-sided
IMC RT. For left-sided RT, IMC inclusion increased the mean percentage dose to 5%
of the heart, but the mean doses to 50% and 90% of the heart were similar. Median
baseline left ventricular ejection fraction (LVEF) was 62% and similar in all groups.
Median absolute decrease in LVEF after RT was 4%, which was not significantly
different according to side or inclusion of IMCs. Trastuzumab was stopped in 11 of
59 patients (18.6%) due to decrease in LVEF. After median follow up of 15 months,
three patients developed clinical congestive heart failure, none of whom received left-
sided IMC RT. CONCLUSIONS: There was no excess acute cardiotoxicity observed
with the combination of left-sided IMC irradiation and concurrent trastuzumab.
[Mh] Termos MeSH Anticorpos Monoclonais/efeitos adversos
primário:
Antineoplásicos/efeitos adversos
Neoplasias da Mama/tratamento farmacológico
Neoplasias da Mama/radioterapia
Quimioterapia Adjuvante/efeitos adversos
Cardiopatias/etiologia
Radioterapia Adjuvante/efeitos adversos
[Mh] Termos MeSH Adulto
secundário:
Idoso

bases.bireme.br/cgi-bin/wxislind.exe/iah/online/ 5/8
25/08/2021 iAH Interface de pesquisa - Lista

Idoso de 80 Anos ou mais

Anticorpos Monoclonais/administração & dosagem
Anticorpos Monoclonais Humanizados
Neoplasias da Mama/patologia
Distribuição de Qui-Quadrado
Terapia Combinada/efeitos adversos
Feminino
Seres Humanos
Linfonodos/patologia
Linfonodos/efeitos da radiação
Meia-Idade
Estudos Retrospectivos
Trastuzumab
Resultado do Tratamento
[Pt] Tipo de
publicação:
JOURNAL ARTICLE
[Nm] Nome de 0 (Antibodies, Monoclonal); 0 (Antibodies, Monoclonal, Humanized); 0
substância:
(Antineoplastic Agents); P188ANX8CK (Trastuzumab)
[Em] Mês de
entrada: 0904
[Cu] Atualização por
classe:
151119
[Lr] Data última
revisão: 151119
[Sb] Subgrupo de
revista:
IM
[Da] Data de entrada
para 081104
processamento:
[St] Status: MEDLINE
[do] DOI: 10.1016/j.radonc.2008.09.003

8/10
[PMID]: 12948167
[Au] Autor: Dietz B; van der Hem KG
[Ad] Endereço: Department of Internal Medicine, Zaans Medical Centre de Heel, PO Box 210, 1500
EE Zaandam, the Netherlands.
[Ti] Título: Late-onset cardiotoxicity of chemotherapy and radiotherapy.
[So] Source: Neth J Med;61(6):228-31, 2003 Jun.
[Is] ISSN: 0300-2977
[Cp] País de
publicação:
Netherlands
[La] Idioma: eng
[Ab] Resumo: An increasing number of patients with malignant lymphoma are becoming long-term
survivors following treatment with chemotherapy (CT) and/or radiotherapy (RT).
Therefore, late therapy-related complications are becoming increasingly clear. We
present three young patients to illustrate the dire consequences of late-onset
cardiotoxicity as sequel to potentially curative treatment. We advise yearly life-long
follow-up of CT/RT patients treated with curative intent. Echocardiography should be
performed when cardiac murmurs arise. Prevention of further cardiac damage by
reducing other cardiac risk factors as well as endocarditis prophylaxis when indicated
is recommended.
[Mh] Termos MeSH Antineoplásicos/efeitos adversos
primário:
Cardiopatias/etiologia
Linfoma/tratamento farmacológico
Linfoma/radioterapia
Radioterapia/efeitos adversos
[Mh] Termos MeSH Adulto
secundário:
Feminino
Seres Humanos
[Pt] Tipo de
publicação: CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de
substância:
0 (Antineoplastic Agents)
[Em] Mês de
entrada: 0310

bases.bireme.br/cgi-bin/wxislind.exe/iah/online/ 6/8
25/08/2021 iAH Interface de pesquisa - Lista
[Cu] Atualização por 041117
classe:
[Lr] Data última
revisão: 041117
[Sb] Subgrupo de
revista:
IM
[Da] Data de entrada
para 030902
processamento:
[St] Status: MEDLINE

9/10
[PMID]: 12067953
[Au] Autor: Meinardi MT; Van Der Graaf WT; Gietema JA; Van Den Berg MP; Sleijfer DT; De
Vries EG; Haaksma J; Boomsma F; Van Veldhuisen DJ
[Ad] Endereço: Department of Medical Oncology, University Hospital Groningen, Groningen,
Netherlands.
[Ti] Título: Evaluation of long term cardiotoxicity after epirubicin containing adjuvant
chemotherapy and locoregional radiotherapy for breast cancer using various
detection techniques.
[So] Source: Heart;88(1):81-2, 2002 Jul.
[Is] ISSN: 1468-201X
[Cp] País de
publicação: England
[La] Idioma: eng
[Mh] Termos MeSH Antibióticos Antineoplásicos/efeitos adversos
primário:
Neoplasias da Mama/tratamento farmacológico
Epirubicina/efeitos adversos
Cardiopatias/induzido quimicamente
[Mh] Termos MeSH Adulto
secundário:
Antibióticos Antineoplásicos/administração & dosagem
Protocolos de Quimioterapia Combinada Antineoplásica/administração & dosagem
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico
Neoplasias da Mama/radioterapia
Quimioterapia Adjuvante
Doença Crônica
Estudos Transversais
Ciclofosfamida/administração & dosagem
Dispneia/induzido quimicamente
Epirubicina/administração & dosagem
Feminino
Fluoruracila/administração & dosagem
Seres Humanos
Assistência de Longa Duração
Meia-Idade
[Pt] Tipo de EVALUATION STUDIES; JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S.
publicação:
GOV'T
[Nm] Nome de 0 (Antibiotics, Antineoplastic); 3Z8479ZZ5X (Epirubicin); 8N3DW7272P
substância:
(Cyclophosphamide); U3P01618RT (Fluorouracil)
[Em] Mês de
entrada: 0208
[Cu] Atualização por
classe: 140612
[Lr] Data última
revisão: 140612
[Sb] Subgrupo de
revista:
AIM; IM
[Da] Data de entrada
para 020618
processamento:
[St] Status: MEDLINE

10/10
[PMID]: 9328157
[Au] Autor: de Graaf H; Dolsma WV; Willemse PH; van der Graaf WT; Sleijfer DT; de Vries EG;
bases.bireme.br/cgi-bin/wxislind.exe/iah/online/ 7/8
25/08/2021 iAH Interface de pesquisa - Lista

Mulder NH
[Ad] Endereço: Department of Internal Medicine, University Hospital Groningen, The Netherlands.
[Ti] Título: Cardiotoxicity from intensive chemotherapy combined with radiotherapy in breast
cancer.
[So] Source: Br J Cancer;76(7):943-5, 1997.
[Is] ISSN: 0007-0920
[Cp] País de
publicação:
England
[La] Idioma: eng
[Ab] Resumo: Cardiac function was evaluated in 86 breast cancer patients after standard
chemotherapy, followed by ablative chemotherapy and chest irradiation. One patient
died of subacute heart failure 3 months after ablative chemotherapy. At a minimum
of 1 year's follow-up (range 1-11 years) left vertricular ejection fraction (LVEF) was
marginally abnormal in 4 of 27 disease-free survivors. One exceptional patient who
received two transplantations is alive, with serious heart failure occurring after the
second ablative chemotherapy. Including this patient, the percentage of patients free
of clinical and subclinical cardiac dysfunction at 7 years is 78% (95% CI 61-95%).
After ablative chemotherapy, cardiotoxicity was rarely life-threatening. The impact of
subclinical cardiotoxicity in the long term is not clear and needs continued
evaluation.
[Mh] Termos MeSH Protocolos de Quimioterapia Combinada Antineoplásica/efeitos adversos
primário:
Neoplasias da Mama/terapia
Coração/efeitos dos fármacos
Função Ventricular Esquerda/efeitos dos fármacos
[Mh] Termos MeSH Adulto
secundário:
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico
Neoplasias da Mama/tratamento farmacológico
Neoplasias da Mama/radioterapia
Terapia Combinada/efeitos adversos
Ciclofosfamida/administração & dosagem
Ciclofosfamida/efeitos adversos
Doxorrubicina/administração & dosagem
Doxorrubicina/efeitos adversos
Epirubicina/administração & dosagem
Epirubicina/efeitos adversos
Feminino
Seres Humanos
Meia-Idade
Pré-Menopausa
Análise de Sobrevida
[Pt] Tipo de
publicação: JOURNAL ARTICLE
[Nm] Nome de 3Z8479ZZ5X (Epirubicin); 80168379AG (Doxorubicin); 8N3DW7272P
substância:
(Cyclophosphamide)
[Em] Mês de
entrada:
9710
[Cu] Atualização por
classe: 140617
[Lr] Data última
revisão:
140617
[Sb] Subgrupo de
revista: IM
[Da] Data de entrada
para 970101
processamento:
[St] Status: MEDLINE

[ Retorna ]

Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde

bases.bireme.br/cgi-bin/wxislind.exe/iah/online/ 8/8